Clinical Trials & Research
Search Clinical Trials
|Title||Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma|
|Description||The purpose of this is to study the side effects and the best dose of vorinostat when given together with combination chemotherapy and rituximab to see how well it works compared to combination chemotherapy and alone in treating patients with previously untreated HIV-related diffuse large B-cell non-Hodgkin lymphoma.|
Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread.
Giving vorinostat together with combination chemotherapy and rituximab may kill more cancer cells.
|Eligibility Criteria||To be eligible for this study, patients must meet several criteria, including but not limited to the following:|
* Patient must be 18 Years and older.
* Patient has histologically or cytologically confirmed diffuse large B-cell non-Hodgkin lymphoma.
* Patient has Serologically confirmed HIV infection by ELISA or western blot, or by another federally approved licensed HIV test
* Patient has life expectancy more than or equal to 2 months
|Principal Investigator||Samir Parekh, MD|
|Contact Name||Dale Wyville, PA|
|Current Trial Type||Interventional|
|Montefiore Clinical Trial||No|
|CHAM Clinical Trial||No|